Blueprint Medicines Corporation (BPMC) Social Stream
BLUEPRINT MEDICINES CORP (BPMC) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BLUEPRINT MEDICINES CORP.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 9 | $136 | $84 | $113.222 | $43.2 | 162.09% |
| 2021-11-10 | 9 | $136 | $84 | $114.444 | $43.2 | 164.92% |
| 2021-11-19 | 9 | $136 | $84 | $115.777 | $43.2 | 168% |
| 2021-11-29 | 9 | $136 | $84 | $115.555 | $43.2 | 167.49% |
| 2022-01-12 | 9 | $135 | $84 | $113.333 | $43.2 | 162.34% |
| 2022-01-25 | 9 | $135 | $84 | $110.555 | $43.2 | 155.91% |
| 2022-01-31 | 9 | $135 | $84 | $108.444 | $43.2 | 151.03% |
| 2022-02-08 | 9 | $135 | $84 | $104.777 | $43.2 | 142.54% |
| 2022-02-17 | 9 | $133 | $82 | $100.625 | $43.2 | 132.93% |
| 2022-03-01 | 10 | $133 | $71 | $97.333 | $43.2 | 125.31% |
| 2022-04-12 | 10 | $133 | $71 | $97.888 | $43.2 | 126.59% |
| 2022-04-28 | 10 | $133 | $68 | $97.555 | $43.2 | 125.82% |
| 2022-05-04 | 10 | $133 | $68 | $96.7 | $43.2 | 123.84% |
| 2022-05-18 | 10 | $152 | $65 | $100.272 | $43.2 | 132.11% |
| 2022-06-01 | 10 | $152 | $65 | $99.363 | $43.2 | 130.01% |
| 2022-06-10 | 10 | $152 | $41 | $96.909 | $43.2 | 124.33% |
| 2022-06-14 | 10 | $152 | $41 | $92.454 | $43.2 | 114.01% |
| 2022-07-27 | 12 | $152 | $40 | $86.461 | $43.2 | 100.14% |
| 2022-08-02 | 10 | $152 | $40 | $86.461 | $43.2 | 100.14% |
| 2022-08-03 | 13 | $152 | $40 | $86.23 | $43.2 | 99.61% |
| 2022-08-17 | 13 | $152 | $40 | $88.214 | $43.2 | 104.2% |
| 2022-08-18 | 13 | $152 | $40 | $87.285 | $43.2 | 102.05% |
| 2022-08-22 | 13 | $152 | $40 | $87.714 | $43.2 | 103.04% |
| 2022-09-06 | 13 | $152 | $40 | $88.428 | $43.2 | 104.69% |
| 2022-10-10 | 14 | $152 | $40 | $89.533 | $43.2 | 107.25% |
| 2022-10-26 | 14 | $152 | $40 | $89.8 | $43.2 | 107.87% |
| 2022-11-02 | 15 | $152 | $40 | $85.133 | $43.2 | 97.07% |
| 2022-11-04 | 16 | $115 | $40 | $78.733 | $43.2 | 82.25% |
The Trend in the Analyst Price Target
BPMC's average price target has moved down $40.96 over the prior 16 months.
BPMC reports an average of 54.57% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-31 | 9 | 135 | 84 | 108.444 | 77.10 | 40.65% |
| 2022-03-22 | 10 | 133 | 71 | 97.888 | 66.50 | 47.2% |
| 2022-05-04 | 10 | 133 | 68 | 97.000 | 63.26 | 53.34% |
| 2022-08-18 | 13 | 152 | 40 | 87.285 | 64.09 | 36.19% |
| 2022-09-06 | 13 | 152 | 40 | 88.428 | 70.66 | 25.15% |
BPMC Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.13 | 9 | 0 | 5 | 2 | 2 | 16 |
The Trend in the Broker Recommendations
BPMC's average broker recommendation rating improved by 0.07 over the prior 123 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BLUEPRINT MEDICINES CORP's average analyst price target is higher than 2731.7% of them.
- BPMC has a greater number of analysts covering the stock than 2604.04% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, BLUEPRINT MEDICINES CORP's variance in analysts' estimates is lower than -2348.54% of them.
- In terms of how BLUEPRINT MEDICINES CORP fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 2409.07% of that group.
Stocks similar to BLUEPRINT MEDICINES CORP in the Pharmaceutical Products industry regarding analyst recommendations and price targets are MCRB, SIOX, and ASND.
View All Top Stocks by Price Target
Is BPMC a Buy, Hold or Sell? See the POWR Ratings now!